V. Calvo

Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment

M. Provencio, M. Torrente, A. Royuela, 2017, Oncotarget.

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

M. Provencio, A. Romero, E. Sánchez-Herrero, 2021, ESMO open.

PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial

J. Bosch-Barrera, M. Provencio, C. Camps, 2022, Journal of Thoracic Oncology.

OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal of Thoracic Oncology.

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.

C. García-Girón, J. Bosch-Barrera, M. Provencio, 2021, European journal of cancer.